MARC details
000 -LEADER |
fixed length control field |
05966naaaa2201453uu 4500 |
001 - CONTROL NUMBER |
control field |
https://directory.doabooks.org/handle/20.500.12854/76594 |
005 - DATE AND TIME OF LATEST TRANSACTION |
control field |
20220714193957.0 |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
International Standard Book Number |
books978-3-0365-1549-6 |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
International Standard Book Number |
9783036515502 |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
International Standard Book Number |
9783036515496 |
024 7# - OTHER STANDARD IDENTIFIER |
Standard number or code |
10.3390/books978-3-0365-1549-6 |
Terms of availability |
doi |
041 0# - LANGUAGE CODE |
Language code of text/sound track or separate title |
English |
042 ## - AUTHENTICATION CODE |
Authentication code |
dc |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
TB |
Source |
bicssc |
100 1# - MAIN ENTRY--PERSONAL NAME |
Personal name |
Silva, Ana Catarina |
Relator code |
edt |
9 (RLIN) |
1620600 |
245 10 - TITLE STATEMENT |
Title |
Preclinical Evaluation of Lipid-Based Nanosystems |
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
Place of publication, distribution, etc |
Basel, Switzerland |
Name of publisher, distributor, etc |
MDPI - Multidisciplinary Digital Publishing Institute |
Date of publication, distribution, etc |
2021 |
300 ## - PHYSICAL DESCRIPTION |
Extent |
1 electronic resource (351 p.) |
506 0# - RESTRICTIONS ON ACCESS NOTE |
Terms governing access |
Open Access |
Source of term |
star |
Standardized terminology for access restriction |
Unrestricted online access |
520 ## - SUMMARY, ETC. |
Summary, etc |
The use of lipid-based nanosystems, including lipid nanoparticles (solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)), nanoemulsions, and liposomes, among others, is widespread. Several researchers have described the advantages of different applications of these nanosystems. For instance, they can increase the targeting and bioavailability of drugs, improving therapeutic effects. Their use in the cosmetic field is also promising, owing to their moisturizing properties and ability to protect labile cosmetic actives. Thus, it is surprising that only a few lipid-based nanosystems have reached the market. This can be explained by the strict regulatory requirements of medicines and the occurrence of unexpected in vivo failure, which highlights the need to conduct more preclinical studies.Current research is focused on testing the in vitro, ex vivo, and in vivo efficacy of lipid-based nanosystems to predict their clinical performance. However, there is a lack of method validation, which compromises the comparison between different studies.This book brings together the latest research and reviews that report on in vitro, ex vivo, and in vivo preclinical studies using lipid-based nanosystems. Readers can find up-to-date information on the most common experiments performed to predict the clinical behavior of lipid-based nanosystems. A series of 15 research articles and a review are presented, with authors from 15 different countries, which demonstrates the universality of the investigations that have been carried out in this area. |
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE |
Terms governing use and reproduction |
Creative Commons |
-- |
https://creativecommons.org/licenses/by/4.0/ |
-- |
cc |
-- |
https://creativecommons.org/licenses/by/4.0/ |
546 ## - LANGUAGE NOTE |
Language note |
English |
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name as entry element |
Technology: general issues |
Source of heading or term |
bicssc |
9 (RLIN) |
928609 |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
nanostructured lipid carriers (NLC) |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
formulation optimization |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
rivastigmine |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
quality by design (QbD) |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
nasal route |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
nose-to-brain |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
N-alkylisatin |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
liposome |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
urokinase plasminogen activator |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
PAI-2 |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
SerpinB2 |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
breast cancer |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
liposomes |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
target delivery nanosystem |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
FZD10 protein |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
colon cancer therapy |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
supersaturation |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
silica-lipid hybrid |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
spray drying |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
lipolysis |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
lipid-based formulation |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
fenofibrate |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
mesoporous silica |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
oral drug delivery |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
hyaluronic acid |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
drug release |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
light activation |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
stability |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
mobility |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
biocorona |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
dissolution enhancement |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
phospholipids |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
solid dosage forms |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
porous microparticles |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
nanoemulsion(s) |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
phase-behavior |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
DoE |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
D-optimal design |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
vegetable oils |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
non-ionic surfactants |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
efavirenz |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
flaxseed oil |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
nanostructured lipid carriers |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
nanocarrier |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
docohexaenoic acid |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
neuroprotection |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
neuroinflammation |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
fluconazole |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Box‒Behnken design |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
nanotransfersome |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
ulcer index |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
zone of inhibition |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
rheological behavior |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
ex vivo permeation |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
nanomedicine |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
cancer |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
doxorubicin |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
melanoma |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
drug delivery |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
ultrasound contrast agents |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
phospholipid coating |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
ligand distribution |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
cholesterol |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
acoustic response |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
microbubble |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
lipid phase |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
dialysis |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
ammonia |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
intoxication |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
cyanocobalamin |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
vitamin B12 |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
atopic dermatitis |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
psoriasis |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
transferosomes |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
lipid vesicles |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
skin topical delivery |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
oligonucleotide |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
self-emulsifying drug delivery systems |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
hydrophobic ion pairing |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
intestinal permeation enhancers |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Caco-2 monolayer |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
clarithromycin |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
solid lipid nanoparticles |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
optimization |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
permeation |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
pharmacokinetics |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
follicular targeting |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
dexamethasone |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
alopecia areata |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
lipomers |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
lipid polymer hybrid nanocapsules |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
biodistribution |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
skin |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
ethyl cellulose |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
n/a |
700 1# - ADDED ENTRY--PERSONAL NAME |
Personal name |
Sousa Lobo, José Manuel |
Relator code |
edt |
9 (RLIN) |
1620601 |
700 1# - ADDED ENTRY--PERSONAL NAME |
Personal name |
Silva, Ana Catarina |
Relator code |
oth |
9 (RLIN) |
1620600 |
700 1# - ADDED ENTRY--PERSONAL NAME |
Personal name |
Sousa Lobo, José Manuel |
Relator code |
oth |
9 (RLIN) |
1620601 |
856 40 - ELECTRONIC LOCATION AND ACCESS |
Host name |
www.oapen.org |
Uniform Resource Identifier |
<a href="https://mdpi.com/books/pdfview/book/4039">https://mdpi.com/books/pdfview/book/4039</a> |
-- |
0 |
Public note |
DOAB: download the publication |
856 40 - ELECTRONIC LOCATION AND ACCESS |
Host name |
www.oapen.org |
Uniform Resource Identifier |
<a href="https://directory.doabooks.org/handle/20.500.12854/76594">https://directory.doabooks.org/handle/20.500.12854/76594</a> |
-- |
0 |
Public note |
DOAB: description of the publication |